<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02989948</url>
  </required_header>
  <id_info>
    <org_study_id>15-2053</org_study_id>
    <nct_id>NCT02989948</nct_id>
  </id_info>
  <brief_title>Physician-Modified Fenestrated and Branched Aortic Endografting for TAAA</brief_title>
  <official_title>Safety and Effectiveness of Physician-Modified Fenestrated and Branched Aortic Endografting for the Treatment of Thoracoabdominal Aortic Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single-arm, traditional feasibility study of a physician-modified fenestrated
      Cook Zenith TX2 aortic endograft base device in adult patients meeting traditional size
      criteria for open surgical treatment of thoracoabdominal aortic aneurysms. Patients meriting
      surgical treatment of their aneurysm that also meet inclusion and exclusion criteria will be
      eligible for enrollment. Patients will be followed for 5 years post procedure. Major adverse
      events will also be recorded by the Sponsor-Investigator and will be monitored by a locally
      appointed Data Monitoring Committee, the Colorado Multiple Institutional Review Board, and
      the FDA.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Patients who Survive at 30 days</measure>
    <time_frame>30 Days</time_frame>
    <description>30 day survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Patients who Development Major Adverse Events at 30 days</measure>
    <time_frame>30 Days</time_frame>
    <description>Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Patients Achieving Treatment Success through 1 year</measure>
    <time_frame>1 Year</time_frame>
    <description>Year one treatment success</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Achieving Technical Success</measure>
    <time_frame>Day of Surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Developing Aneurysm rupture</measure>
    <time_frame>Day of Surgery</time_frame>
    <description>Aneurysm rupture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Necessitating Conversion to Open Repair</measure>
    <time_frame>Day of Surgery</time_frame>
    <description>This is assessed intraoperatively. In case of a device deployment failure or intraoperative aneurysm rupture, emergent conversion to open repair via laparotomy, thoracotomy, or thoracoabdominal aortic exposure may become necessary. Patients undergoing such intraoperative conversion will be considered to have met this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Suffering Access Site Complication (Femoral or Iliac)</measure>
    <time_frame>Day of Surgery</time_frame>
    <description>If femoral or iliac rupture occurs intraoperatively, or if femoral or iliac flow-limiting dissection or occlusion is identified intraoperatively or on the day of surgery, patients will be considered to have met this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Developing Lower Extremity Ischemia</measure>
    <time_frame>Day of Surgery</time_frame>
    <description>This will be assess intraoperatively and on the day of surgery. If patients have lower extremity pulses either absent or diminished compared to baseline, with associated pain, sensory deficits or motor deficits on clinical evaluation, patients will be considered to have met this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Developing Lower Extremity Compartment Syndrome</measure>
    <time_frame>Day of Surgery</time_frame>
    <description>In patients with lower extremity pain to passive motion post-operatively, invasive pressure measurement of the four calf compartments will be performed. If compartment pressures are greater than 30 in any compartment, patients will be considered to have met this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Developing Stroke</measure>
    <time_frame>Day of Surgery</time_frame>
    <description>In patients with altered mental status or lateralizing motor or sensory deficits, MRI of the brain will be performed. If diffusion weighted MRI imaging demonstrates an intracranial lesion, a modified Rankin score will be calculated. If MRS is 2 or greater, patients will be considered to have met this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Developing Paraplegia</measure>
    <time_frame>Day of Surgery</time_frame>
    <description>Patients with complete absence of lower extremity motor function in one or both legs will be considered to have met this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Developing Paraparesis</measure>
    <time_frame>Day of Surgery</time_frame>
    <description>Patients will undergo lower extremity motor strength assessment post-operatively on a standard 0 to 5 scale. If greater than 0 but less than 5 in either extremity, patients will be considered to have met this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients who die during surgery</measure>
    <time_frame>Day of Surgery</time_frame>
    <description>Death during surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients who Survive</measure>
    <time_frame>At 90, 183 days; 1, 2, 3, 4 and 5 years</time_frame>
    <description>Survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients that Development Major Adverse Events</measure>
    <time_frame>At 90, 183 days; 1, 2, 3, 4 and 5 years</time_frame>
    <description>Major Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Achieving Treatment Success</measure>
    <time_frame>At 30, 90, 183 days; 2, 3, 4 and 5 years</time_frame>
    <description>Treatment success</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Aortic Aneurysm, Thoracoabdominal</condition>
  <arm_group>
    <arm_group_label>Physician-modified fenestrated and branched aortic endograft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Physician-modified fenestrated endografting for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Physician-modified fenestrated and branched aortic endograft</intervention_name>
    <description>Physician-modified fenestrated endografting for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.</description>
    <arm_group_label>Physician-modified fenestrated and branched aortic endograft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be a man or woman 50 years of age or older by the date of informed consent.

          2. Must have a thoracoabdominal aortic aneurysm of any Crawford classification (extent
             I-V) that extends no more proximal than the left subclavian artery.

          3. Must have an aneurysm size that meets standard indications for surgical repair (6.0 cm
             in maximum diameter in the descending thoracic aorta, or 5.5 cm in maximum diameter in
             the abdominal aorta).

          4. Must be considered, in the judgment of the S-I, to be a high risk candidate for open
             surgical repair.

          5. Must not be a candidate for repair under the Instructions for Use of a commercially
             available, FDA-approved endovascular graft.

          6. Patient or their LAR must be able to provide informed consent.

          7. Must be able to comply with the five year study assessment schedule of events.

          8. Must have a non-aneurysm-related life expectancy, in the judgment of the S-I, of
             greater than 2 years.

        Exclusion Criteria:

          1. Aneurysm due to acute or chronic dissection, intramural hematoma, penetrating aortic
             ulceration, pseudoaneurysm, mycotic aneurysm, or traumatic transection.

          2. Ruptured or acutely symptomatic aortic aneurysm.

          3. Known connective tissue disorder.

          4. Imaging demonstrating any of the following:

               -  Lack of 20 mm non-aneurysmal proximal seal zone (zone 3, or zone 2 with a
                  carotid-subclavian bypass or transposition).

               -  Lack of 15 mm non-aneurysmal distal seal zone(s) (aortic, common iliac, or
                  external iliac).

               -  Branch vessel target (renal, superior mesenteric, or celiac) &lt; 5 mm or &gt; 10 mm in
                  average diameter.

               -  Untreated left subclavian artery stenosis or occlusion.

               -  Untreated unilateral or bilateral hypogastric artery occlusion.

               -  Signs that the inferior mesenteric artery is indispensable.

               -  Have branching, duplication, aneurysm, or untreatable stenosis of the celiac,
                  superior mesenteric artery, or renal arteries that would preclude implantation of
                  the investigational devices.

          5. Known allergy to stainless steel or polyester.

          6. History of anaphylaxis to contrast, with inability to prophylax appropriately.

          7. Have uncorrectable coagulopathy.

          8. Have unstable angina.

          9. Have a body habitus that would inhibit X-ray visualization of the aorta.

         10. Have a major surgical or interventional procedure unrelated to the treatment of the
             aneurysm planned â‰¤30 days of the endovascular repair.

         11. Known to be participating in any other clinical study which may affect performance of
             this device.

         12. Known or visible pregnancy.

         13. Contraindication to oral antiplatelet therapy.

         14. Prisoners or those on alternative sentencing.

         15. Known systemic infection with potential for endovascular graft infection.

         16. Anticipated need for MRI scanning within 3 months of insertion of investigational
             product.

         17. Other conditions or comorbidities that, in the opinion of the Sponsor-Investigator,
             would exclude the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P. Kuwayama, M.D., M.P.A.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tracey A MacDermott, BA, BS, CCRC</last_name>
    <phone>303-724-2757</phone>
    <email>tracey.macdermott@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tracey MacDermott</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracey MacDermott, BA, BS, CCRC</last_name>
      <phone>303-724-2757</phone>
      <email>tracey.macdermott@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Darci Dreiling, MHA</last_name>
      <phone>303-724-2690</phone>
      <email>darci.dreiling@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David P. Kuwayama, M.D., M.P.A.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Crawford ES, Coselli JS. Thoracoabdominal aneurysm surgery. Semin Thorac Cardiovasc Surg. 1991 Oct;3(4):300-22.</citation>
    <PMID>1793767</PMID>
  </reference>
  <reference>
    <citation>Safi HJ, Miller CC 3rd. Spinal cord protection in descending thoracic and thoracoabdominal aortic repair. Ann Thorac Surg. 1999 Jun;67(6):1937-9; discussion 1953-8.</citation>
    <PMID>10391343</PMID>
  </reference>
  <reference>
    <citation>Dapunt OE, Galla JD, Sadeghi AM, Lansman SL, Mezrow CK, de Asla RA, Quintana C, Wallenstein S, Ergin AM, Griepp RB. The natural history of thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 1994 May;107(5):1323-32; discussion 1332-3.</citation>
    <PMID>8176976</PMID>
  </reference>
  <reference>
    <citation>Kuzmik GA, Sang AX, Elefteriades JA. Natural history of thoracic aortic aneurysms. J Vasc Surg. 2012 Aug;56(2):565-71. doi: 10.1016/j.jvs.2012.04.053.</citation>
    <PMID>22840907</PMID>
  </reference>
  <reference>
    <citation>Clouse WD, Hallett JW Jr, Schaff HV, Gayari MM, Ilstrup DM, Melton LJ 3rd. Improved prognosis of thoracic aortic aneurysms: a population-based study. JAMA. 1998 Dec 9;280(22):1926-9.</citation>
    <PMID>9851478</PMID>
  </reference>
  <reference>
    <citation>Cowan JA Jr, Dimick JB, Henke PK, Rectenwald J, Stanley JC, Upchurch GR Jr. Epidemiology of aortic aneurysm repair in the United States from 1993 to 2003. Ann N Y Acad Sci. 2006 Nov;1085:1-10.</citation>
    <PMID>17182917</PMID>
  </reference>
  <reference>
    <citation>O'Callaghan A, Mastracci TM, Eagleton MJ. Staged endovascular repair of thoracoabdominal aortic aneurysms limits incidence and severity of spinal cord ischemia. J Vasc Surg. 2015 Feb;61(2):347-354.e1. doi: 10.1016/j.jvs.2014.09.011. Epub 2014 Oct 23.</citation>
    <PMID>25449006</PMID>
  </reference>
  <reference>
    <citation>Lee JT, Lee GK, Chandra V, Dalman RL. Comparison of fenestrated endografts and the snorkel/chimney technique. J Vasc Surg. 2014 Oct;60(4):849-56; discussion 856-7. doi: 10.1016/j.jvs.2014.03.255. Epub 2014 Apr 27.</citation>
    <PMID>24785682</PMID>
  </reference>
  <reference>
    <citation>Greenberg R, Eagleton M, Mastracci T. Branched endografts for thoracoabdominal aneurysms. J Thorac Cardiovasc Surg. 2010 Dec;140(6 Suppl):S171-8. doi: 10.1016/j.jtcvs.2010.07.061.</citation>
    <PMID>21092788</PMID>
  </reference>
  <reference>
    <citation>Greenberg RK, Lu Q, Roselli EE, Svensson LG, Moon MC, Hernandez AV, Dowdall J, Cury M, Francis C, Pfaff K, Clair DG, Ouriel K, Lytle BW. Contemporary analysis of descending thoracic and thoracoabdominal aneurysm repair: a comparison of endovascular and open techniques. Circulation. 2008 Aug 19;118(8):808-17. doi: 10.1161/CIRCULATIONAHA.108.769695. Epub 2008 Aug 4.</citation>
    <PMID>18678769</PMID>
  </reference>
  <reference>
    <citation>Matsumura JS, Melissano G, Cambria RP, Dake MD, Mehta S, Svensson LG, Moore RD; Zenith TX2 Clinical Trial Investigators. Five-year results of thoracic endovascular aortic repair with the Zenith TX2. J Vasc Surg. 2014 Jul;60(1):1-10. doi: 10.1016/j.jvs.2014.01.043. Epub 2014 Mar 14.</citation>
    <PMID>24636714</PMID>
  </reference>
  <reference>
    <citation>Riga CV, McWilliams RG, Cheshire NJ. In situ fenestrations for the aortic arch and visceral segment: advances and challenges. Perspect Vasc Surg Endovasc Ther. 2011 Sep;23(3):161-5. doi: 10.1177/1531003510388421. Epub 2011 Apr 17. Review.</citation>
    <PMID>21502107</PMID>
  </reference>
  <reference>
    <citation>Oderich GS, Greenberg RK. Endovascular iliac branch devices for iliac aneurysms. Perspect Vasc Surg Endovasc Ther. 2011 Sep;23(3):166-72. doi: 10.1177/1531003511408344. Epub 2011 Aug 1. Review.</citation>
    <PMID>21810808</PMID>
  </reference>
  <reference>
    <citation>Chuter T, Greenberg RK. Standardized off-the-shelf components for multibranched endovascular repair of thoracoabdominal aortic aneurysms. Perspect Vasc Surg Endovasc Ther. 2011 Sep;23(3):195-201. doi: 10.1177/1531003511430397. Review.</citation>
    <PMID>22205654</PMID>
  </reference>
  <reference>
    <citation>Oderich GS, Greenberg RK. The evolving options for endovascular repair of complex aortic aneurysms. Foreword. Perspect Vasc Surg Endovasc Ther. 2011 Sep;23(3):145-8. doi: 10.1177/1531003511407343.</citation>
    <PMID>22205653</PMID>
  </reference>
  <reference>
    <citation>O'Brien N, Sobocinski J, d'Elia P, Guillou M, Maioli F, Azzaoui R, Haulon S. Fenestrated endovascular repair of type IV thoracoabdominal aneurysms: device design and implantation technique. Perspect Vasc Surg Endovasc Ther. 2011 Sep;23(3):173-7. doi: 10.1177/1531003511408340. Epub 2011 Aug 1. Review.</citation>
    <PMID>21810817</PMID>
  </reference>
  <reference>
    <citation>Browne TF, Hartley D, Purchas S, Rosenberg M, Van Schie G, Lawrence-Brown M. A fenestrated covered suprarenal aortic stent. Eur J Vasc Endovasc Surg. 1999 Nov;18(5):445-9.</citation>
    <PMID>10610834</PMID>
  </reference>
  <reference>
    <citation>Haulon S, D'Elia P, O'Brien N, Sobocinski J, Perrot C, Lerussi G, Koussa M, Azzaoui R. Endovascular repair of thoracoabdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2010 Feb;39(2):171-8. doi: 10.1016/j.ejvs.2009.11.009. Epub 2009 Nov 27.</citation>
    <PMID>19945316</PMID>
  </reference>
  <reference>
    <citation>Starnes BW. Physician-modified endovascular grafts for the treatment of elective, symptomatic, or ruptured juxtarenal aortic aneurysms. J Vasc Surg. 2012 Sep;56(3):601-7. doi: 10.1016/j.jvs.2012.02.011. Epub 2012 May 2.</citation>
    <PMID>22554425</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2016</study_first_submitted>
  <study_first_submitted_qc>December 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2016</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endovascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>No plan to share IPD exists at this time.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

